Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, was approved for sale in the United States by the FDA in May 2014. It is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children. Trimel is also developing Tefina™, a use-as-required testosterone nasal gel for the treatment of female orgasmic disorder. Tefina™ has completed a number of clinical studies, including a large Phase II trial in April 2014, where the product positively showed statistical significance and was found to be well-tolerated. In July 2014, Trimel acquired the Canadian rights to Estrace® (17-beta estradiol), a product indicated for the treatment of symptomatic relief of menopausal symptoms.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:TRLPF
- CUSIP: N/A
- Web: www.aceruspharma.com
- Market Cap: $18.33 million
- Outstanding Shares: 213,118,000
- 50 Day Moving Avg: $0.09
- 200 Day Moving Avg: $0.09
- 52 Week Range: $0.07 - $0.20
Sales & Book Value:
- Trailing P/E Ratio: 8.600
- Foreward P/E Ratio: Infinity
- P/E Growth: 0.000
- Annual Revenue: $15.35 million
- Price / Sales: 1.19
- Book Value: $0.05 per share
- Price / Book: 1.72
- EBIDTA: $5.28 million
- Net Margins: 45.53%
- Return on Equity: 24.59%
- Return on Assets: 10.47%
- Debt-to-Equity Ratio: 0.20%
- Current Ratio: 1.97%
- Quick Ratio: 1.14%
- Average Volume: 21,606 shs.
- Beta: 1.42
Frequently Asked Questions for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
What is Trimel Pharmaceuticals Corp.'s stock symbol?
Trimel Pharmaceuticals Corp. trades on the OTCMKTS under the ticker symbol "TRLPF."
How were Trimel Pharmaceuticals Corp.'s earnings last quarter?
Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) released its quarterly earnings results on Wednesday, March, 18th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.02. Trimel Pharmaceuticals Corp. had a net margin of 45.53% and a return on equity of 24.59%. View Trimel Pharmaceuticals Corp.'s Earnings History.
Who are some of Trimel Pharmaceuticals Corp.'s key competitors?
Some companies that are related to Trimel Pharmaceuticals Corp. include Tokai Pharmaceuticals (NVUS), OmniComm Systems (OMCM), Chiasma (CHMA), Ohr Pharmaceuticals (OHRP), ReWalk Robotics Ltd (RWLK), EnteroMedics (ETRM), Trillium Therapeutics (TRIL), TrovaGene (TROV), Can Fite Biopharma Ltd (CANF), Auris Medical Holding AG (EARS), Tonix Pharmaceuticals Holding Corp. (TNXP), Mirna Therapeutics (MIRN), Check-Cap (CHEK), Catabasis Pharmaceuticals (CATB), Marinus Pharmaceuticals (MRNS), Alcobra (ADHD), Cesca Therapeutics (KOOL) and Ocera Therapeutics (OCRX).
How do I buy Trimel Pharmaceuticals Corp. stock?
Shares of Trimel Pharmaceuticals Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trimel Pharmaceuticals Corp.'s stock price today?
MarketBeat Community Rating for Trimel Pharmaceuticals Corp. (OTCMKTS TRLPF)MarketBeat's community ratings are surveys of what our community members think about Trimel Pharmaceuticals Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Trimel Pharmaceuticals Corp. stock can currently be purchased for approximately $0.09.
Consensus Ratings for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
(Data available from 6/29/2015 forward)
|3/22/2017||Roth Capital||Reiterated Rating||Buy|
Earnings History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)Earnings History by Quarter for Trimel Pharmaceuticals Corp. (OTCMKTS TRLPF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Current Year EPS Consensus Estimate: $-0.02 EPS
Dividend History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Latest Headlines for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Trimel Pharmaceuticals Corp. (TRLPF) Chart for Thursday, June, 29, 2017